Prepared by: Research Desk. Sources are linked for verification.

Status: Investigational. Retatrutide is not approved by the FDA. The agency states it has "not been found safe and effective for any condition" [13]. See our approval status page for the current regulatory picture.

The glucagon receptor is the feature that separates retatrutide from the incretin drugs before it. Semaglutide acts on one receptor (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). Retatrutide adds a third: the glucagon receptor, often abbreviated GCGR [9].

This page is about that receptor. It covers where the receptor is found, how it signals, what it does to glucose, amino-acid and fat metabolism, and what kind of evidence sits behind claims about energy expenditure. For how the three receptor activities are combined in one molecule, see Retatrutide mechanism of action: one molecule, three receptors.

What the glucagon receptor is

Glucagon is a hormone released by the alpha cells of the pancreas. It was identified roughly a century ago. For most of that time it was described mainly as insulin's counterpart, the signal that raises blood glucose during fasting [2]. Its receptor, GCGR, belongs to the class B family of G-protein-coupled receptors. This is the same broad family that includes the GLP-1 and GIP receptors [1].

Where it is expressed. Reviews of glucagon physiology describe the liver as the main site of GCGR expression and the main site of glucagon action. Expression is also reported in the kidney and, at lower levels, in other tissues [1]. Reported expression outside the liver depends partly on the detection method used. That is one reason the importance of direct glucagon action in tissues such as fat remains less settled than its action in the liver [1][3].

How the receptor signals: cAMP and protein kinase A

When glucagon binds GCGR, the receptor mainly couples to the stimulatory G protein Gs. This activates adenylyl cyclase and raises intracellular cyclic AMP (cAMP). cAMP activates protein kinase A (PKA). PKA then changes the activity of metabolic enzymes directly and alters gene expression through transcription factors such as CREB [1][3].

The result is a coordinated shift in liver cell metabolism that unfolds over two timescales:

• Within minutes: changes in enzyme activity.

• Over hours: changes in which genes are switched on.

Hepatic glucose output

The best-established effect of glucagon receptor activation is increased glucose release from the liver. It works through two routes [1][3]:

• Glycogenolysis: breaking down stored glycogen into glucose.

• Gluconeogenesis: making new glucose from precursors such as amino acids, lactate and glycerol.

Glucagon also suppresses glycogen synthesis. Together these actions raise hepatic glucose output, which is the reason glucagon matters in fasting physiology [1].

The same property creates a design problem for drug developers. Sustained, unopposed activation of the receptor would be expected to push blood glucose upward. Reviews of glucagon-based drug candidates describe this as the central trade-off of the approach [6].

Amino-acid metabolism and the liver–alpha cell axis

Newer research gives glucagon a major role in amino-acid handling. Reviews describe glucagon as promoting amino-acid uptake and breakdown in the liver, including ureagenesis, the conversion of amino-acid nitrogen into urea [2][3].

Researchers describe a feedback loop called the liver–alpha cell axis:

1. Glucagon drives the liver to clear amino acids.

2. Circulating amino acids stimulate glucagon secretion from alpha cells.

3. When glucagon signalling is disrupted, plasma amino-acid levels rise, and in animal studies alpha cells expand [2][3].

This axis is one reason reviewers argue that glucagon's role goes well beyond glucose mobilization [3]. It is still an active research area, and much of the mechanistic detail comes from animal models.

Lipid metabolism in the liver

GCGR activation also shifts liver metabolism toward burning fat rather than storing it. Reviews of hepatic glucagon action report three main changes [3]:

• Inhibited de novo lipogenesis (making new fat).

• Promoted fatty-acid oxidation.

• Increased ketone production.

These findings are a main reason the glucagon receptor drew interest in research on liver fat accumulation. In a phase 2a substudy, investigators measured liver fat content in participants receiving retatrutide [12]. The study reported its findings as measured changes in liver fat over the study period, not as an established clinical outcome.

Energy expenditure: what kind of evidence exists

Glucagon is often described as raising energy expenditure. That is part of the stated rationale for adding glucagon activity to an incretin drug [6][9]. The evidence behind this claim is uneven, and most of it comes from animal studies.

• Mouse studies. In one study, diet-induced obese mice received GLP-1 receptor agonism and glucagon receptor agonism. The authors reported metabolic effects that were "distinct and complementary" between the two [7]. Another study looked at female mice. It reported sex-specific responses to glucagon receptor agonism and examined the FGF21–glucagon axis as part of the mechanism [8]. Proposed contributors to the energy-expenditure effect include fatty-acid oxidation, FGF21 signalling and brown-fat activity [1][8].

• Human data. Human studies of glucagon's effect on energy expenditure have generally been small. Effects vary with species, exposure and study setting [1][6].

The fair summary is that increased energy expenditure is a plausible design rationale with animal and limited human support. Large trials have not shown that every glucagon-receptor agonist produces a meaningful increase in human energy expenditure.

Why GLP-1 activity is paired with glucagon activity

If glucagon raises glucose, why put it in a metabolic drug? The answer in the literature is pairing.

GLP-1 receptor activation does three relevant things [4][5]:

• Enhances insulin secretion when glucose is elevated (glucose-dependent insulin release).

• Suppresses glucagon secretion from alpha cells.

• Slows gastric emptying and reduces food intake.

These actions push in the opposite direction from glucagon's effect on hepatic glucose output.

The concept behind co-agonists is to combine glucagon's fuel-mobilizing and fat-oxidizing actions with incretin-driven glucose control. Reviews frame the main design question as finding a "sweet spot": the ratio of glucagon to GLP-1 activity at which the glucose-raising effect stays offset [6].

Retatrutide adds GIP receptor activity to this pair, making it a triple agonist [9]. Other molecules combining GLP-1 and glucagon receptor activity, including survodutide, mazdutide and pemvidutide, have also been studied. Each uses its own balance of receptor activities, so findings from one molecule do not carry over automatically to another.

Where retatrutide's trial record fits

Published retatrutide studies give context for how the glucagon component behaves in people:

• Phase 2 obesity trial. Adults with obesity took part in a 48-week trial, and investigators reported changes in body weight compared with placebo [10].

• Phase 2 type 2 diabetes trial. This trial measured glycated haemoglobin and body weight against placebo and an active comparator [11]. It is relevant to the glucose question because glucose control was measured directly despite the glucagon component.

• Phase 2a liver fat substudy. This substudy reported measured changes in liver fat [12].

• TRIUMPH-2. This phase 3 trial in adults with obesity and type 2 diabetes was published in 2026 [14].

On tolerability, the phase 2 obesity trial reported gastrointestinal events as the most common adverse events. It also reported increases in heart rate [10]. For a structured summary, see Retatrutide side effects: what the trial reports list. For guidance on interpreting placebo-adjusted results, see How to read a retatrutide trial. Our broader retatrutide guide covers each trial in more detail.

None of these results makes retatrutide an approved product. The FDA states it cannot be used in compounding under federal law [13].

Further reading: metabolism and endocrinology books

Primary research papers assume a lot of background knowledge. A good metabolism or endocrinology textbook fills in that background: receptor families, second-messenger signalling, liver fuel handling and endocrine feedback loops. With that foundation, journal reviews become much easier to follow.

When comparing textbooks, these criteria are useful:

• Edition date. Endocrine and metabolic science has moved quickly, especially on hormones such as glucagon. A recent edition is more likely to cover the amino-acid feedback loop described above.

• Depth on signalling. Look for chapters that explain receptor coupling, cAMP and protein kinase cascades step by step, not just name them.

• Referencing. Books that cite primary literature make it easy to trace a claim back to its source.

• Figures and format. Clear pathway diagrams matter for metabolism. E-book versions are searchable, while print versions are often easier to annotate.

• Price transparency. Compare used, rental and digital prices. Older editions are cheaper, but check what changed between editions.

For a wider list covering energy balance and body weight regulation, see our reading list on obesity science. How we choose and disclose recommendations is explained on our About page.

Frequently asked questions

What does the glucagon receptor do?

It is the receptor through which glucagon acts, mainly in the liver. Activation raises cAMP and PKA signalling, which increases glucose release, speeds amino-acid breakdown and shifts the liver toward fat oxidation [1][3].

Why would a metabolic drug include glucagon activity if glucagon raises blood glucose?

The design pairs glucagon activity with GLP-1 activity, which enhances glucose-dependent insulin release and suppresses glucagon secretion [4][5]. Researchers describe the goal as balancing the two so the glucose-raising effect is offset [6].

Is the energy-expenditure effect of glucagon proven in humans?

Not conclusively. Most supporting data come from animal studies, and human studies have been small, with effects that vary by setting [1][7][8].

Is retatrutide approved?

No. Retatrutide is investigational, and the FDA says it has not been found safe and effective for any condition [13]. Our approval status page tracks filings and timelines.

Related on this site

• Retatrutide, trial by trial

• Retatrutide mechanism of action: one molecule, three receptors

• Retatrutide side effects: what the trial reports list

• Retatrutide: mechanism, trial findings and side effects explained

• Is retatrutide FDA approved? Legal status and approval timeline

• Retatrutide vs tirzepatide: how the trial designs and data compare

Last updated: 22 October 2026.

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.